NASDAQ · CAI
Healthcare · Biotechnology
$32.35
Up+$1.25 (+4.00%)
Updated Oct 22, 2026, 8:35 AM
SID Score
6.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CAI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 21, 2026
CAI closed at $32.35 after 21 trading sessions, up 2.21% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 21, 2026 | $31.11 | $32.75 | $30.925 | $32.35 | 2.23M |
| Oct 20, 2026 | $30.71 | $31.56 | $30.10 | $31.11 | 3.54M |
| Oct 19, 2026 | $31.26 | $31.99 | $30.62 | $30.71 | 2.1M |
| Oct 16, 2026 | $31.76 | $32.40 | $30.155 | $30.56 | 2.73M |
| Oct 15, 2026 | $29.50 | $32.15 | $28.80 | $31.76 | 3.55M |
| Oct 14, 2026 | $29.23 | $31.53 | $29.0225 | $30.255 | 4.35M |
| Oct 13, 2026 | $29.48 | $29.78 | $28.665 | $29.53 | 3.52M |
| Oct 12, 2026 | $29.94 | $30.13 | $28.49 | $29.69 | 5M |
| Oct 9, 2026 | $27.82 | $29.84 | $27.67 | $29.70 | 5.03M |
| Oct 8, 2026 | $26.75 | $27.615 | $25.8702 | $27.50 | 3.86M |
| Oct 7, 2026 | $27.10 | $27.56 | $26.065 | $27.10 | 4.88M |
| Oct 6, 2026 | $30.69 | $32.56 | $27.285 | $27.455 | 4.75M |
| Oct 5, 2026 | $28.30 | $30.46 | $28.30 | $30.39 | 4.96M |
| Oct 2, 2026 | $28.72 | $28.97 | $28.07 | $28.30 | 3.2M |
| Oct 1, 2026 | $30.60 | $30.96 | $28.29 | $28.35 | 4.41M |
| Sep 30, 2026 | $31.40 | $32.04 | $30.60 | $30.63 | 2.93M |
| Sep 29, 2026 | $31.64 | $32.325 | $30.82 | $31.55 | 3.71M |
| Sep 28, 2026 | $31.73 | $32.09 | $30.88 | $31.75 | 3.94M |
| Sep 25, 2026 | $32.65 | $32.77 | $31.585 | $31.98 | 2.92M |
| Sep 24, 2026 | $31.34 | $32.405 | $30.91 | $32.27 | 5.98M |
| Sep 23, 2026 | $31.12 | $32.89 | $31.10 | $31.65 | 4.36M |
The latest Smart Investors Daily articles mentioning CAI.
Company
Market Activity
Research & News
CAI research
Company profile and research snapshot.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Canaccord Genuity | Hold | — |
| Oct 14, 2026 | JP Morgan | Overweight | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 15, 2026
Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026.
Yahoo · Oct 14, 2026
Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.
Benzinga · Oct 13, 2026
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.
Yahoo · Oct 2, 2026
Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAI.
